NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee C meeting minutes

**Minutes:** Confirmed

**Date and time:** Tuesday 2 August 2022

**Location:** Via Zoom

## Attendees

Committee members present

1. Professor Stephen O’Brien (Chair) Present for all items
2. Dr Richard Nicholas (Vice Chair) Present for all items
3. Emtiyaz Chowdhury Present for all items
4. Dr Prithwiraj Das Items 1 to 4.2.2 & 5.1.3 to 5.2.2
5. Chamkhor Dhillon Present for all items
6. Dr Rob Forsyth Present for all items
7. Dr Pedro Saramago Goncalves Present for all items
8. John Hampson Present for all items
9. Dr Nigel Langford Items 4.1.3 to 5.2.2
10. Iain McGowan Present for all items
11. Stella O’Brien Present for all items
12. Malcolm Oswald Items 5 to 5.2.2
13. Professor Subhash Pokhrel Present for all items
14. Professor Matthew Stevenson Present for all items
15. Professor Paul Tappenden Present for all items

NICE staff present

Ross Dent, Associate Director Present for all items

Louise Jafferally, Project Manager Present for all items

Kate Moore, Project Manager Items 4.1.3 & 5.1 to 5.1.3

Louise Crathorne, Heath Technology Assessment Adviser Present for all items

Owen Swales, Heath Technology Assessment Analyst Present for all items

Anna Willis, Heath Technology Assessment Analyst Present for all items

Anita Sangha, Heath Technology Assessment Analyst Present for all items

Benjamin Gregory, Business Analyst, RIA Items 5 to 5.2.2

Ella Livingstone, Technical Analyst, Commercial Risk Assessment Present for all items

Korin Knight, Senior Medical Editor Items 1 to 5.2.2

Anna Sparshatt, Senior Medical Editor Items 5 to 5.2.2

Rosalee Mason, Coordinator, MIP Items 1 to 4.1.3 & 5 to 5.1.3

Emma Gordon, Coordinator, MIP Items 1 to 4.1.3 & 5 to 5.1.3

Catherine Pank, Assistant Project Manager, COT Items 5 to 5.2.2

Gemma Smith, Coordinator, COT Items 1 to 4.2.2

Laura Kelly, Administrator, COT Present for all items

Iain Cannell, Administrator, TA Present for all items

Ayla Hudson, Apprentice, TA & COT Items 1 to 4.2.2

External assessment group representatives present

Susan O’Meara, Kleijnen Systematic Reviews Ltd Items 1 to 4.1.3

Isaac Corro Ramos, Kleijnen Systematic Reviews Ltd Items 1 to 4.1.3

Robert Wolff, Kleijnen Systematic Reviews Ltd Items 5 to 5.1.3

Willem Witlox, Kleijnen Systematic Reviews Ltd Items 5 to 5.1.3

NHS England expert present

Professor Peter Clark, Cancer Drugs Fund Lead, NSH England, Present for all items

Observers present

Dr Radha Todd, Incoming TAC A Chair, NICE Present for all items

Kendall Jamieson Gilmour, Associate Director, NICE Items 1 to 4.2.2

## Minutes

### Introduction to the meeting

* 1. The chair, Professor Stephen O’Brien, welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted committee member apologies.

### News and announcements

* 1. None

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 5 July 2022

### Appraisal of tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma [ID3795]

* 1. Part 1 – Open session
     1. The chair welcomed the invited NHSE expert, external assessment group representatives, members of the public and company representatives from Incyte Corporation.
     2. The chair asked all committee members and expert, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Dr Richard Nicholas declared financial interests as he has attended paid advisory boards with Novartis and Roche (named comparator companies) in an unrelated disease area (MS). It was agreed that this declaration would not prevent Dr Nicholas from taking part in the discussion.
* No further interests were declared for this appraisal
  + 1. The Chair led a discussion of the consultation comments presented to the committee.
  1. Part 2 – Closed session (company representatives, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course:

<https://www.nice.org.uk/guidance/indevelopment/gid-ta10645>

### Appraisal of oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy [ID3892]

* 1. Part 1 – Open session
     1. The chair Professor Stephen O’Brien welcomed the invited NHSE expert, external assessment group representatives, members of the public and company representatives from Celgene, a BMS company.
     2. The chair asked all committee members and expert, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Dr Richard Nicholas declared a direct financial interest as he has attended paid advisory boards with Novartis and Roche (named comparator companies) in an unrelated disease area (multiple sclerosis). It was agreed that this declaration would not prevent Dr Nicholas from taking part in the discussion.
* Committee member observer Dr Radha Todd declared a direct financial interest as she was a member of a Pfizer advisory board from September to November 2021. It was agreed that this declaration would not prevent Dr Todd from observing the discussion.
* Committee member Emtiyaz Chowdhury declared professional and personal interests as he is currently in a recruitment process for Incyte. If any offer or role were to be accepted, it would not start until October 2022. Parexel is a CRO that regularly works with industry to support clinical trials. he has not had any direct involvement or knowledge of any support provided by Parexel to Celgene or Incyte for the technology under discussion today. It was agreed that this declaration would not prevent Emtiyaz from taking part in the discussion.
* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by the chair.
  1. Part 2 – Closed session (company representatives, external assessment group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course:

<https://www.nice.org.uk/guidance/indevelopment/gid-ta10775>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee C will be held on Tuesday 6 September 2022 and will start promptly at 09:30.